Physician profile
Kyle A Darnell
NPI 1255520524
$10,443.58
in general payments reported to CMS, 2019-2025
31 companies · $923 in 2025
The $923 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $220 · 2020: $118 · 2021: $835 · 2022: $1,122 · 2023: $2,008 · 2024: $5,219 · 2025: $923.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,017 · Food and Beverage: $2,364 · Travel and Lodging: $1,568 · Consulting Fee: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,017.38 |
| Food and Beverage | $2,363.57 |
| Travel and Lodging | $1,568.07 |
| Consulting Fee | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $5,838.87 | 2023-2025 | Da Vinci Surgical System |
| Glaxosmithkline, LLC. | $992.29 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $653.95 | 2019-2023 | Breztri, Fasenra, Tezspire |
| Inogen, INC. | $500.67 | 2022-2025 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Takeda Pharmaceuticals U.S.A., INC. | $353.43 | 2020-2023 | Glassia |
| Genzyme Corporation | $267.16 | 2019-2023 | |
| Grifols USA, LLC | $218.73 | 2022-2024 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $203.39 | 2019-2023 | Ofev |
| Bayer Healthcare Pharmaceuticals INC. | $200.00 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $169.75 | 2021-2025 | Dupixent |
| Pulmonx Corporation | $147.53 | 2021-2025 | Chartis Catheter, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| Philips North America LLC | $126.39 | 2021-2025 | Vest Therapy Und |
| United Therapeutics Corporation | $123.95 | 2021-2023 | Tyvaso |
| Actelion Pharmaceuticals US, INC. | $94.11 | 2020-2023 | Opsumit |
| Genentech USA, INC. | $78.94 | 2019-2023 | Xolair |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Resmed Corp | $54.08 | 2021-2023 | |
| Baxter Healthcare | $53.43 | 2023 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Fisher & Paykel Healthcare INC | $52.22 | 2024 | Fisher & Paykel Healthcare |
| Medical Device Business Services, INC. | $43.93 | 2023 | Na |
| Mylan Specialty L.P. | $40.11 | 2023 | Yupelri |
| Insmed, INC. | $37.20 | 2025 | Brinsupri, Arikayce |
| Vanda Pharmaceuticals INC. | $34.38 | 2022 | |
| Ethicon INC. | $31.52 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $25.47 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $16.22 | 2019 | |
| Merck Sharp & Dohme LLC | $16.03 | 2022 | |
| Lilly USA, LLC | $15.71 | 2025 | Zepbound |
| Circassia INC. | $15.07 | 2020 | |
| Electromed, INC. | $13.33 | 2022 | |
| Livanova USA, INC. | $13.02 | 2023 | Lifesparc |
| Amgen INC. | $12.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Darnell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.